Close Menu

NEW YORK ─ LightDeck Diagnostics said it is poised to enter the human diagnostic testing space as it sketches plans to launch rapid antigen and antibody assays to detect SARS-CoV-2 at the point of care.

The Boulder, Colorado-based point-of-care testing company is planning to market an instrument and test cartridges that provide results in five minutes for clinics, physician office labs, long-term care facilities, urgent care settings, and possibly non-traditional channels such as prisons, its CEO and founder Chris Myatt said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.